FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164989226> ?p ?o ?g. }

• W3164989226 endingPage "23" @default.
• W3164989226 startingPage "16" @default.
• W3164989226 abstract "<b><i>Background/Aims:</i></b> The study aim was to evaluate if mTOR inhibitors can be considered as a treatment option for HR+ HER2− metastatic breast cancer (MBC) after progression on CDK4/6 inhibitors in clinical practice. <b><i>Methods:</i></b> We retrospectively collected the clinicopathological data of patients with HR+ HER2− MBC treated with CDK4/6 inhibitors and subsequent therapies at our institution between 2014 and 2020. The patients were divided into 3 groups according to the type of subsequent treatment: (A) exemestane plus everolimus, (B) endocrine monotherapy, and (C) chemotherapy. Overall survival (OS) was estimated by using the Kaplan-Meier method and compared by using the log-rank test. The efficacy and adverse events (AEs) of each subsequent treatment were assessed by using Fisher’s exact tests. <b><i>Results:</i></b> Eighty-six patients (34 in group A, 20 in group B, 32 in group C) were included. The most common endocrine therapy in group B was fulvestrant (40%). The major chemotherapy regimen in group C was eribulin (25%). The median OS times after stopping CDK4/6 inhibitors were 34.5 months (95% confidence interval, 17.2 to NA), 13.6 months (3.9 to NA), and 19.5 months (18.8 to NA) in group A, group B, and group C, respectively. The only significant difference in OS was observed between group A and group B (20.9 months; <i>p</i> = 0.003). There was no difference in the incidence of grade 3 AEs between groups A and C or in the frequency of treatment discontinuation because of AEs among the 3 groups. <b><i>Conclusion:</i></b> Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2− MBC previously treated with CDK4/6 inhibitors." @default.
• W3164989226 created "2021-06-07" @default.
• W3164989226 creator A5003584988 @default.
• W3164989226 creator A5015316489 @default.
• W3164989226 creator A5029247118 @default.
• W3164989226 creator A5087402935 @default.
• W3164989226 creator A5091706082 @default.
• W3164989226 date "2021-05-21" @default.
• W3164989226 modified "2023-09-25" @default.
• W3164989226 title "Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors" @default.
• W3164989226 cites W2019607817 @default.
• W3164989226 cites W2127152525 @default.
• W3164989226 cites W2151082560 @default.
• W3164989226 cites W2167188058 @default.
• W3164989226 cites W2185043285 @default.
• W3164989226 cites W2290950904 @default.
• W3164989226 cites W2404884142 @default.
• W3164989226 cites W2552099557 @default.
• W3164989226 cites W2560635244 @default.
• W3164989226 cites W2620993107 @default.
• W3164989226 cites W2763875663 @default.
• W3164989226 cites W2767035762 @default.
• W3164989226 cites W2806592404 @default.
• W3164989226 cites W2896846857 @default.
• W3164989226 cites W2902401096 @default.
• W3164989226 cites W2945564879 @default.
• W3164989226 cites W2948574507 @default.
• W3164989226 cites W2961694923 @default.
• W3164989226 cites W2969690362 @default.
• W3164989226 cites W3016495342 @default.
• W3164989226 cites W3024073709 @default.
• W3164989226 cites W3024513991 @default.
• W3164989226 cites W3027984788 @default.
• W3164989226 cites W3081949673 @default.
• W3164989226 cites W3083198770 @default.
• W3164989226 cites W4206666777 @default.
• W3164989226 doi "https://doi.org/10.1159/000515729" @default.
• W3164989226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35355705" @default.
• W3164989226 hasPublicationYear "2021" @default.
• W3164989226 type Work @default.
• W3164989226 sameAs 3164989226 @default.
• W3164989226 citedByCount "1" @default.
• W3164989226 countsByYear W31649892262023 @default.
• W3164989226 crossrefType "journal-article" @default.
• W3164989226 hasAuthorship W3164989226A5003584988 @default.
• W3164989226 hasAuthorship W3164989226A5015316489 @default.
• W3164989226 hasAuthorship W3164989226A5029247118 @default.
• W3164989226 hasAuthorship W3164989226A5087402935 @default.
• W3164989226 hasAuthorship W3164989226A5091706082 @default.
• W3164989226 hasBestOaLocation W31649892261 @default.
• W3164989226 hasConcept C121608353 @default.
• W3164989226 hasConcept C126322002 @default.
• W3164989226 hasConcept C143998085 @default.
• W3164989226 hasConcept C207103383 @default.
• W3164989226 hasConcept C2775860665 @default.
• W3164989226 hasConcept C2775930923 @default.
• W3164989226 hasConcept C2776387010 @default.
• W3164989226 hasConcept C2776694085 @default.
• W3164989226 hasConcept C2777176818 @default.
• W3164989226 hasConcept C2777785397 @default.
• W3164989226 hasConcept C44249647 @default.
• W3164989226 hasConcept C530470458 @default.
• W3164989226 hasConcept C71924100 @default.
• W3164989226 hasConcept C90924648 @default.
• W3164989226 hasConceptScore W3164989226C121608353 @default.
• W3164989226 hasConceptScore W3164989226C126322002 @default.
• W3164989226 hasConceptScore W3164989226C143998085 @default.
• W3164989226 hasConceptScore W3164989226C207103383 @default.
• W3164989226 hasConceptScore W3164989226C2775860665 @default.
• W3164989226 hasConceptScore W3164989226C2775930923 @default.
• W3164989226 hasConceptScore W3164989226C2776387010 @default.
• W3164989226 hasConceptScore W3164989226C2776694085 @default.
• W3164989226 hasConceptScore W3164989226C2777176818 @default.
• W3164989226 hasConceptScore W3164989226C2777785397 @default.
• W3164989226 hasConceptScore W3164989226C44249647 @default.
• W3164989226 hasConceptScore W3164989226C530470458 @default.
• W3164989226 hasConceptScore W3164989226C71924100 @default.
• W3164989226 hasConceptScore W3164989226C90924648 @default.
• W3164989226 hasIssue "1" @default.
• W3164989226 hasLocation W31649892261 @default.
• W3164989226 hasLocation W31649892262 @default.
• W3164989226 hasLocation W31649892263 @default.
• W3164989226 hasOpenAccess W3164989226 @default.
• W3164989226 hasPrimaryLocation W31649892261 @default.
• W3164989226 hasRelatedWork W2017141930 @default.
• W3164989226 hasRelatedWork W2092771806 @default.
• W3164989226 hasRelatedWork W2138700542 @default.
• W3164989226 hasRelatedWork W2196426442 @default.
• W3164989226 hasRelatedWork W2754732635 @default.
• W3164989226 hasRelatedWork W2769343627 @default.
• W3164989226 hasRelatedWork W2782589310 @default.
• W3164989226 hasRelatedWork W2912143634 @default.
• W3164989226 hasRelatedWork W3160156778 @default.
• W3164989226 hasRelatedWork W4322771458 @default.
• W3164989226 hasVolume "17" @default.
• W3164989226 isParatext "false" @default.
• W3164989226 isRetracted "false" @default.
• W3164989226 magId "3164989226" @default.

• next